Targeting the PI3K/Akt/mTOR pathway with the pan-Akt inhibitor GDC-0068 in PIK3CA-mutant breast cancer brain metastases
出版年份 2019 全文链接
标题
Targeting the PI3K/Akt/mTOR pathway with the pan-Akt inhibitor GDC-0068 in PIK3CA-mutant breast cancer brain metastases
作者
关键词
-
出版物
NEURO-ONCOLOGY
Volume -, Issue -, Pages -
出版商
Oxford University Press (OUP)
发表日期
2019-06-06
DOI
10.1093/neuonc/noz105
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- The Dual PI3K/mTOR Pathway Inhibitor GDC-0084 Achieves Antitumor Activity in PIK3CA-Mutant Breast Cancer Brain Metastases
- (2019) Franziska M. Ippen et al. CLINICAL CANCER RESEARCH
- Buparlisib is a brain penetrable pan-PI3K inhibitor
- (2018) Mark C. de Gooijer et al. Scientific Reports
- Three dimensional primary cultures for selecting human breast cancers that are sensitive to the anti-tumor activity of ipatasertib or taselisib in combination with anti-microtubule cytotoxic drugs
- (2018) M. Orditura et al. BREAST
- Randomized Phase II Study Evaluating Akt Blockade with Ipatasertib, in Combination with Abiraterone, in Patients with Metastatic Prostate Cancer with and without PTEN Loss
- (2018) Johann S. de Bono et al. CLINICAL CANCER RESEARCH
- Ipatasertib plus paclitaxel versus placebo plus paclitaxel as first-line therapy for metastatic triple-negative breast cancer (LOTUS): a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial
- (2017) Sung-Bae Kim et al. LANCET ONCOLOGY
- Phosphatidylinositol 3-kinase (PI3Kα)/AKT axis blockade with taselisib or ipatasertib enhances the efficacy of anti-microtubule drugs in human breast cancer cells
- (2017) Floriana Morgillo et al. Oncotarget
- Genetic Characterization of Brain Metastases in the Era of Targeted Therapy
- (2017) Catherine H. Han et al. Frontiers in Oncology
- Impact of Blood-Brain Barrier Integrity on Tumor Growth and Therapy Response in Brain Metastases
- (2016) M. Osswald et al. CLINICAL CANCER RESEARCH
- A First-in-Human Phase I Study of the ATP-Competitive AKT Inhibitor Ipatasertib Demonstrates Robust and Safe Targeting of AKT in Patients with Solid Tumors
- (2016) Cristina Saura et al. Cancer Discovery
- Metastatic Competence Can Emerge with Selection of Preexisting Oncogenic Alleles without a Need of New Mutations
- (2015) Leni S. Jacob et al. CANCER RESEARCH
- Integrated genomic and transcriptomic analysis of human brain metastases identifies alterations of potential clinical significance
- (2015) Jodi M Saunus et al. JOURNAL OF PATHOLOGY
- Genomic Characterization of Brain Metastases Reveals Branched Evolution and Potential Therapeutic Targets
- (2015) P. K. Brastianos et al. Cancer Discovery
- Ex vivo Evans blue assessment of the blood brain barrier in three breast cancer brain metastasis models
- (2014) John Do et al. BREAST CANCER RESEARCH AND TREATMENT
- Antagonism of EGFR and HER3 Enhances the Response to Inhibitors of the PI3K-Akt Pathway in Triple-Negative Breast Cancer
- (2014) J. J. Tao et al. Science Signaling
- Targeting Activated Akt with GDC-0068, a Novel Selective Akt Inhibitor That Is Efficacious in Multiple Tumor Models
- (2013) J. Lin et al. CLINICAL CANCER RESEARCH
- Evaluation and Clinical Analyses of Downstream Targets of the Akt Inhibitor GDC-0068
- (2013) Y. Yan et al. CLINICAL CANCER RESEARCH
- mTORC1 Inhibition Is Required for Sensitivity to PI3K p110 Inhibitors in PIK3CA-Mutant Breast Cancer
- (2013) M. Elkabets et al. Science Translational Medicine
- Targeting the PI3K pathway for cancer therapy
- (2012) Navid Sadeghi et al. Future Medicinal Chemistry
- Discovery and Preclinical Pharmacology of a Selective ATP-Competitive Akt Inhibitor (GDC-0068) for the Treatment of Human Tumors
- (2012) James F. Blake et al. JOURNAL OF MEDICINAL CHEMISTRY
- AKT Inhibition Relieves Feedback Suppression of Receptor Tyrosine Kinase Expression and Activity
- (2011) Sarat Chandarlapaty et al. CANCER CELL
- PI3K inhibition results in enhanced HER signaling and acquired ERK dependency in HER2-overexpressing breast cancer
- (2011) V Serra et al. ONCOGENE
- Adjuvant Whole-Brain Radiotherapy Versus Observation After Radiosurgery or Surgical Resection of One to Three Cerebral Metastases: Results of the EORTC 22952-26001 Study
- (2010) Martin Kocher et al. JOURNAL OF CLINICAL ONCOLOGY
- Association between gain-of-function mutations in PIK3CA and resistance to HER2-targeted agents in HER2-amplified breast cancer cell lines
- (2009) Y. Kataoka et al. ANNALS OF ONCOLOGY
- Knockin of mutant PIK3CA activates multiple oncogenic pathways
- (2009) John P. Gustin et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started